

Reference: FOI.ICB-2425/086

Subject: Weight Loss Drugs

*I can confirm that the ICB **does not hold the information requested**; please see responses below:*

QUESTION	RESPONSE
1. How many GP appointments were taken where an overdose of either Saxenda, ozempic or Wegovy (medical names Liraglutide and semaglutide) weightloss drugs were given as a reason for the appointment in every year between 2018 and 2023. Please give a figure for each year.	The ICB does not hold this information. This information may be held by individual practices.
2. How many A&E attendances were there where an overdose of either Saxenda, ozempic or Wegovy (medical names Liraglutide and semaglutide) weightloss drugs were given as a reason for the attending in every year between 2018 and 2023. Please give a figure for each year.	The ICB does not hold this information. We advise contacting the Acute Hospital Trusts directly; North Bristol NHS Trust (NBT) - https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information
3. How many deaths were recorded where an overdose of either Saxenda, ozempic or Wegovy (medical names Liraglutide and semaglutide) weightloss drugs were given as a reason in every year between 2018 and 2023. Please give a figure for each year.	University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) - https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests

The information provided in this response is accurate as of 12 June 2024 and has been approved for release by Dave Jarrett, Chief Delivery Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.